The objective of the OASIS 7 CURRENT study was to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death, stroke, and myocardial infarction) after a percutaneous coronary intervention.

The CURRENT-OASIS 7 (Clopidogrel optimal loading dose Usage to Reduce Recurrent EveNTs-Organization to Assess Strategies in Ischemic Syndromes) study will be the first adequately powered randomized trial to determine the efficacy and safety of higher dose compared with lower dose ASA and clopidogrel for treatment of ACS.

Primary endpoint:

First occurrence of cardiovascular death, myocardial infarction and stroke up to 30 days.

Secondary endpoints: major bleeding and the net efficacy to safety balance of death, MI, stroke, or severe bleeding at 30 days. All primary and secondary endpoints are adjudicated.

Study Type

Interventional - Drug

Study Design

Randomized double-blind douse comparison, factorial

NO. of Countries


NO. of Sites


NO. of Participants


Study Period

2006 - 2009



Back To Top